Autologous T-cell immunotherapy for patients with solid tumor cancers that extracts patients' active T cells, expands and enriches them, then reinfuses them to boost anti-tumor immunity. Platform therapies include PBL-T and RIV-8 developed to overcome prior limitations of T-cell treatments in solid tumors.